Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug ...